Literature DB >> 8451761

Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors.

S M Storm1, U R Rapp.   

Abstract

We demonstrate here consistent point mutations of the c-raf-1 proto-oncogene, within a small region of the kinase domain, in a mouse model for chemical tumor induction. This is the first demonstration of point mutated raf genes in vivo, and the first isolation of activating in vivo point mutations in the kinase domain of a proto-oncogene. The specific region where these mutations are clustered also has biological significance. This is precisely the region where 5/5 independently generated monoclonal antibodies raised against Raf-1 map to [29], and predictions based upon the crystal structure of A kinase identify this as the substrate pocket. The tumors examined show a selective specificity for Raf-1 mutations in that another family of genes, the ras proto-oncogenes which are frequently activated by point mutation in both animal and human tumors [15-21,26], is not involved. Our consistent finding of Raf-1 mutations in a mouse tumor model also has consequences for further evaluation of the role of Raf-1 in human tumor development, as it emphasizes the need to examine c-raf-1 at the sequence level. In fact preliminary screening of human lung tumors indicates point mutations at amino acid 533 (John Lyons, personal communication). Finally, the cumulative data on the critical role of Raf-1 in signal transduction and the occurrence of oncogenic Raf-1 in tumors [32-41] highlight this enzyme as an attractive target for development of novel anticancer regimens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8451761     DOI: 10.1016/0378-4274(93)90056-4

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  11 in total

Review 1.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Raf family kinases: old dogs have learned new tricks.

Authors:  David Matallanas; Marc Birtwistle; David Romano; Armin Zebisch; Jens Rauch; Alexander von Kriegsheim; Walter Kolch
Journal:  Genes Cancer       Date:  2011-03

3.  Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.

Authors:  R M Przygodzki; S D Finkelstein; J C Langer; P A Swalsky; N Fishback; A Bakker; D G Guinee; M Koss; W D Travis
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

4.  KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Jochen Gaedcke; Marian Grade; Klaus Jung; Markus Schirmer; Peter Jo; Christoph Obermeyer; Hendrik A Wolff; Markus K Herrmann; Tim Beissbarth; Heinz Becker; Thomas Ried; Michael Ghadimi
Journal:  Radiother Oncol       Date:  2009-11-11       Impact factor: 6.280

5.  CRAF R391W is a melanoma driver oncogene.

Authors:  Mohammad Atefi; Bjoern Titz; Jennifer Tsoi; Earl Avramis; Allison Le; Charles Ng; Anastasia Lomova; Amanda Lassen; Michael Friedman; Bartosz Chmielowski; Antoni Ribas; Thomas G Graeber
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

Review 6.  MicroRNA-195: a review of its role in cancers.

Authors:  Wanpeng Yu; Xiao Liang; Xiangdong Li; Yuan Zhang; Zhenqing Sun; Ying Liu; Jianxun Wang
Journal:  Onco Targets Ther       Date:  2018-10-17       Impact factor: 4.147

7.  MYC is a metastasis gene for non-small-cell lung cancer.

Authors:  Ulf R Rapp; Christian Korn; Fatih Ceteci; Christiaan Karreman; Katharina Luetkenhaus; Valentina Serafin; Emanuele Zanucco; Inês Castro; Tamara Potapenko
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

8.  Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

Authors:  Moizza Mansoor; Alirio J Melendez
Journal:  Gene Regul Syst Bio       Date:  2008-09-22

9.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

Authors:  Roland Houben; Jürgen C Becker; Andreas Kappel; Patrick Terheyden; Eva-B Bröcker; Rudolf Goetz; Ulf R Rapp
Journal:  J Carcinog       Date:  2004-03-26

10.  RTK/ERK pathway under natural selection associated with prostate cancer.

Authors:  Yang Chen; Xianxiang Xin; Jie Li; Jianfeng Xu; Xiaoxiang Yu; Tianyu Li; Zengnan Mo; Yanling Hu
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.